Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.

Janice M.Mehnert，医学博士，临床研究副主任，黑色素瘤和 纽约大学珀尔穆特癌症中心(PCC)皮肤肿瘤学和终身医学教授 兰贡健康/纽约大学格罗斯曼医学院。在这里，她致力于推动 NCI赞助的临床研究。她活跃在NCI赞助的临床试验网络中，包括 国家临床试验网络(NCTN)，她在那里担任东方合作肿瘤科 美国放射影像学会黑色素瘤和皮肤委员会 联合主席，以及早期治疗临床试验网络(ET-CTN)，在那里她担任站点PI 监督PCC的ET-CTN临床试验工作。她主持并出版了多个调查者 启动了方案，其中许多方案得到了NCI的支持，并展示了指导初级调查人员的记录。 作为AD，Mehnert博士负责监管曼哈顿、长岛(Li)、 和贝尔维尤医院中心(监督现场医务主任和临床试验办公室(CTO)行政 董事和工作人员)、CTO资源分配、PCC研究方案的优先顺序以及对PCC的监督 12个疾病管理小组(DMGs)。她还完成了未来临床研究的战略规划。 活动包括PCC布鲁克林校区的活动。自从她加入PCC以来，她一直带头 重组临床研究基础设施，减少试验激活时间，并组装 支持PCC-Li第一阶段试验活动的资源。她让PCC参与了NCI发起的倡议，以促进 公平获得临床试验机会。她成功地争取到了创建目标访问权限的资金 针对未得到充分服务的人群的癌症治疗(追赶)计划，该计划使她迅速启动了20 ET-CTN试验和组装预筛选基础设施，以导航种族和民族多样性和 对ET-CTN方案服务不足的患者。她随后领导了将PCC整合到DANA的工作 法伯-哈佛癌症中心领导学术组织(UM1CA186709)作为附属组织。 在这份申请中，她概述了计划1)促进PCC调查人员领导NCI的机会- 赞助的临床试验；2)促进NCI赞助的试验的收益，包括提交NCTN 领先学术参与网站(LAPS)赠款，3)促进公平获得临床试验和4) 促进公平获得研究机会。她还概述了改善沟通的计划 提供试验服务，增加获得精确医学试验的机会，并发展信息技术 简化研究流程的方法。R50临床研究专家奖将允许PCC 以保护Mehnert博士从事这些研究活动的时间。她对这些目标的实现将会增加 PCC研究人员和PCC患者获得NCI赞助的试验和临床研究机会，a 对PCC临床研究企业和NCI临床研究使命的重大奖励。

Janice M. Mehnert, M.D., is the Associate Director (AD) for Clinical Research, Director, Melanoma and Cutaneous Oncology and a tenured Professor of Medicine at the Perlmutter Cancer Center (PCC) of NYU Langone Health/NYU Grossman School of Medicine. Here, she engages in significant efforts to promote NCI-sponsored clinical research. She is active within NCI sponsored clinical trials networks, including the National Clinical Trials Network (NCTN), where she serves as the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) Melanoma and Skin Committee Co-Chair, and the Early Therapeutics Clinical Trials Network (ET-CTN), where she serves as site PI overseeing PCC’s ET-CTN clinical trial efforts. She has conducted and published multiple investigator initiated protocols, many with NCI support, and demonstrated a track record of mentoring junior investigators. As AD, Dr. Mehnert is responsible for the supervision of clinical trial operations in Manhattan, Long Island (LI), and Bellevue Hospital Center (overseeing site Medical Directors and Clinical Trials Office (CTO) Administrative Directors and staff), CTO resource allocation, prioritization of PCC’s research protocols and oversight of PCC’s 12 Disease Management Groups (DMGs). She also completes strategic planning for future clinical research activities including those at PCC’s Brooklyn campus. Since her recruitment to PCC, she has spearheaded the reorganization of the clinical research infrastructure, decreased trial activation timelines, and assembled resources to support Phase I trial activity at PCC-LI. She engaged PCC in NCI-sponsored initiatives to promote equitable access to clinical trials. She successfully competed for funding for the Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP) Program, which allowed her to rapidly activate 20 ET-CTN trials and assemble a prescreening infrastructure to navigate racially and ethnically diverse and underserved patients to ET-CTN protocols. She subsequently led the integration of PCC into the Dana Farber-Harvard Cancer Center Lead Academic Organization (UM1CA186709) as an Affiliate Organization. In this application, she outlines plans to 1) Promote opportunities for PCC investigators to lead NCI- sponsored clinical trials; 2) Promote accrual to NCI sponsored trials, including the submission of a NCTN Lead Academic Participating Site (LAPS) grant, 3) Promote equitable access to clinical trials and 4) Promote equitable access to research opportunities. She also outlines plans to improve communication of trial offerings, increase access to precision medicine trials, and develop information technology approaches to streamline research processes. The R50 Clinical Research Specialist Award would allow PCC to protect Dr. Mehnert’s time to pursue these research activities. Her accomplishment of these goals will increase access for PCC investigators and PCC patients to NCI sponsored trials and clinical research opportunities, a significant reward for the PCC clinical research enterprise and the NCI clinical research mission.